Results 21 to 30 of about 265,886 (307)

Neoadjuvant immunotherapy for melanoma

Journal of Surgical Oncology, 2020
AbstractClinical trials have demonstrated the efficacy of immunotherapy, especially checkpoint blockade inhibitors, in the treatment of patients with metastatic melanoma. More recently, improvements in survival have been reported in patients with high‐risk resectable melanoma when these agents are used in the adjuvant setting.
Ann Y. Lee, Mary S. Brady
openaire   +3 more sources

Current status and novel directions in triple negative breast cancer patients. Risk factors. Role of the platinum-based chemotherapy [PDF]

Romanian Journal of Medical Practice, 2016
Rationale. Breast cancer (BC) has been recognized to be the most common type of cancer in women all over the world. One of the most aggressive subtype of BC is the triple negative breast cancer (TNBC) which is defined by the absence of estrogen receptor (
Olivia IONESCU, Irina BALESCU, Nicolae BACALBASA   +2 more
doaj   +1 more source

Efficacy and safety of neoadjuvant immunotherapy in resectable esophageal or gastroesophageal junction carcinoma: A pooled analysis of prospective clinical trials

Frontiers in Immunology, 2022
Neoadjuvant chemoradiotherapy (NCRT) plus radical esophagectomy is currently the standard treatment for resectable esophageal or gastroesophageal junction (GEJ) carcinoma.
Jie Zhu, Xuefeng Leng, Binyang Gao, Bo Wang, Hanlin Zhang, Lei Wu, Jiabao Ma, Yan Tan, Lin Peng, Yongtao Han, Qifeng Wang   +10 more
doaj   +1 more source

miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer

Molecular Oncology, 2019
One of the hallmarks of cancer is sustained angiogenesis. Favorable results have been reported in some breast cancer (BC) patients receiving antiangiogenic therapy with bevacizumab (Bev) in combination with chemotherapy, and further knowledge on how Bev ...
Evita Maria Lindholm, Miriam Ragle Aure, Mads Haugland Haugen, Kristine Kleivi Sahlberg, Vessela N. Kristensen, Daniel Nebdal, Anne‐Lise Børresen‐Dale, Ole Christian Lingjærde, Olav Engebraaten   +8 more
doaj   +1 more source

Perioperative systemic therapies for non-small-cell lung cancer: Recent advances and future perspectives

Frontiers in Surgery, 2023
The mainstay of treatment for early-stage non-small-cell lung cancer (NSCLC) is surgical resection. Traditionally, chemotherapy has been used perioperatively in locally extensive disease to improve the oncologic outcomes of surgery, with a 5-year ...
Savvas Lampridis, Marco Scarci
doaj   +1 more source

Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery in locally advanced rectal cancer: preliminary results of a phase II study [PDF]

, 2018
PURPOSE: To report preliminary results of induction chemotherapy (IC) followed by neoadjuvant chemoradiotherapy (CRT) and surgery in locally advanced rectal cancer (LARC) patients.MATERIALS AND METHODS: This is the preliminary evaluation of a phase II ...
Benevento, Ilaria, Bulzonetti, Nadia, Cortesi, Enrico, D'Ambrosio, Giancarlo, De Felice, Francesca, Iafrate, Franco, Iannitti, Marcella, Mancini, Marialaura, Marampon, Francesco, Marzo, Marco, Musio, Daniela, Tombolini, Vincenzo, Urbano, Federica   +12 more
core   +1 more source

Neoadjuvant/presurgical treatments [PDF]

Breast Cancer Research, 2008
In this article the term 'neoadjuvant' is used to describe pre-operative treatment for 3 months or more for large (usually ≥ 3 cm) operable cancers before surgery. Clinical response and pathological response are important end-points. The term 'presurgical' refers to treatment of short duration (around 2 weeks) before surgery, sometimes referred to as a
openaire   +2 more sources

Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. [PDF]

, 2014
BackgroundSipuleucel-T is a US Food and Drug Administration-approved immunotherapy for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Its mechanism of action is not fully understood.
Amling, Christopher L, Carroll, Peter, Chan, Stephen, Corman, John, Fong, Lawrence, Frohlich, Mark W, Lewis, Jera, Sheikh, Nadeem A, Simko, Jeffrey, Sims, Robert B, Small, Eric J, Stephenson, Robert A, Weinberg, Vivian   +12 more
core   +2 more sources

Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5 [PDF]

, 2017
Background The purpose of this study was to determine the cardiac safety and clinical activity of trastuzumab and bevacizumab with docetaxel after epirubicin with cyclophosphamide (EC) in patients with HER2-positive locally advanced breast cancer (LABC ...
Ansari, Bilal, Buyse, Marc E., Conlin, Alison K., Geyer, Charles E., Jr., Gross, Howard M., Jacobs, Samuel A., Keogh, George P., Lord, Raymond S., Mamounas, Eleftherios P., Mauquoi, Celine, Patocskai, Erica J., Polikoff, Jonathan A., Rastogi, Priya, Robidoux, André, Smith, John W., Stella, Philip J., Swain, Sandra M., Wolmark, Norman   +17 more
core   +2 more sources

Antitumor efficacy of silver nanoparticles reduced with β-D-glucose as neoadjuvant therapy to prevent tumor relapse in a mouse model of breast cancer

Frontiers in Pharmacology
Introduction: Neoadjuvant therapy constitutes a valuable modality for diminishing tumor volume prior to surgical resection. Nonetheless, its application encounters limitations in the context of recurrent tumors, which manifest resistance to conventional ...
Moisés Armides Franco Molina, David Reding Hernández, Paola Leonor García Coronado, Jorge R. Kawas, Diana G. Zárate Triviño, Sara Paola Hernández Martínez, Beatriz Elena Castro Valenzuela, Cristina Rodríguez Padilla   +7 more
doaj   +1 more source